Sorafenib is a multi-target inhibitor actively against BRAF, vascular endothelial growth factor receptor 2/3, PDGFR, and KITTrp557_Lys558del/Thr670Ile mutant expressed in Ba/F3 system and also has the activity to suppress the growth of GIST with KIT exon 11 fragment deletion in xenograft mouse model [12]–[14]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.